Post

Biotech’s road to recovery with 46% increase in Q1 venture funding

Private biotech venture financing saw a 46% increase in total deal value in the first quarter (Q1) of 2024 compared …

J&J expands atopic dermatitis scope with $1.25bn Numab antibody purchase

Johnson & Johnson (J&J) is once again targeting atopic dermatitis, gaining the global rights to Numab Therapeutics’ investigational first-in-class antibody, …

How logistics service providers add value for pharma companies

The pharmaceutical industry faces myriad challenges affecting its supply chain, from stringent regulatory requirements to the urgent need for agility …

ASCO 2024: J&J’s early radioligand prostate cancer trial reports four patient deaths

Johnson & Johnson’s (J&J) prostate cancer radiotherapy JNJ-6420 outlook was hampered by safety issues that resulted in four deaths in …

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

US-based Rakuten Medical has announced positive interim data from the Phase Ib/II trial of its photoimmunotherapy, ASP-1929, in combination with …